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Abstract
Background: Changes in immune function believed to contribute to a variety of age-related diseases have been
associated with increased production of nitric oxide (NO). We have recently reported that proteasome inhibitors
(dexamethasone, mevinolin, quercetin, δ-tocotrienol, and riboflavin) can inhibit lipopolysaccharide (LPS)-induced NO
production in vitro by RAW 264.7 cells and by thioglycolate-elicited peritoneal macrophages derived from four strains of
mice (C57BL/6, BALB/c, LMP7/MECL-1
-/- and PPAR-a
-/- knockout mice). The present study was carried out in order to
further explore the potential effects of diet supplementation with naturally-occurring inhibitors (δ-tocotrienol and
quercetin) on LPS-stimulated production of NO, TNF-a, and other pro-inflammatory cytokines involved in the ageing
process. Young (4-week-old) and senescent mice (42-week old) were fed control diet with or without quercetin (100
ppm), δ-tocotrienol (100 ppm), or dexamethasone (10 ppm; included as positive control for suppression of
inflammation) for 4 weeks. At the end of feeding period, thioglycolate-elicited peritoneal macrophages were collected,
stimulated with LPS, LPS plus interferon-b (IFN-b), or LPS plus interferon-g (IFN-g), and inflammatory responses assessed
as measured by production of NO and TNF-a, mRNA reduction for TNF-a, and iNOS genes, and microarray analysis.
Results: Thioglycolate-elicited peritoneal macrophages prepared after four weeks of feeding, and then challenged
with LPS (10 ng or 100 ng) resulted in increases of 55% and 73%, respectively in the production of NO of 46-week-old
compared to 8-week-old mice fed control diet alone (respective control groups), without affecting the secretion of
TNF-a among these two groups. However, macrophages obtained after feeding with quercetin, δ-tocotrienol, and
dexamethasone significantly inhibited (30% to 60%; P < 0.02) the LPS-stimulated NO production, compared to
respective control groups. There was a 2-fold increase in the production of NO, when LPS-stimulated macrophages
of quercetin, δ-tocotrienol, or dexamethasone were also treated with IFN-b or IFN-g compared to respective control
groups. We also demonstrated that NO levels and iNOS mRNA expression levels were significantly higher in LPS-
stimulated macrophages from senescent (0.69 vs 0.41; P < 0.05), compared to young mice. In contrast, age did not
appear to impact levels of TNF-a protein or mRNA expression levels (0.38 vs 0.35) in LPS-stimulated macrophages.
The histological analyses of livers of control groups showed lesions of peliosis and microvesicular steatosis, and
treated groups showed Councilman body, and small or large lymphoplasmacytic clusters.
Conclusions: The present results demonstrated that quercetin and δ-tocotrienols inhibit the LPS-induced NO
production in vivo. The microarray DNA analyses, followed by pathway analyses indicated that quercetin or δ-
tocotrienol inhibit several LPS-induced expression of several ageing and pro-inflammatory genes (IL-1b, IL-1a, IL-6,
TNF-a, IL-12, iNOS, VCAM1, ICAM1, COX2, IL-1RA, TRAF1 and CD40). The NF-B pathway regulates the production
of NO and inhibits the pro-inflammatory cytokines involved in normal and ageing process. These ex vivo results
confirmed the earlier in vitro findings. The present findings of inhibition of NO production by quercetin and δ-
tocotrienol may be of clinical significance treating several inflammatory diseases, including ageing process.
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In recent years, the concept that age-associated diseases
(e.g. cancer, cardiovascular disease, dementia) might be
attributable, in part, to dysregulated inflammatory
responses has been the subject of extensive discussion
[1]. We have studied the host inflammatory response to
endotoxin (lipopolysaccharide = LPS) for many years,
and recently have focused on the role of the protea-
somes in regulating LPS-induced inflammatory
responses in various systems [2,3]. Consequently, we
were intrigued by a report that LPS-stimulated macro-
phages from senescent (22-month-old) mice produce
approximately 10 times more nitric oxide (NO) than
similarly stimulated macrophages from 2-month-old
mice [4], as we have demonstrated that proteasome
inhibitors can suppress NO production by murine
macrophages [3]. Specifically, we have identified a vari-
ety of naturally-occurring proteasome inhibitors that
have the capacity to suppress LPS-induced production
of NO and secretion of TNF-a, as well as signaling
pathways leading to production of TNF-a and other
pro-inflammatory cytokines in RAW 264.7 cells, and
thioglycolate-elicited peritoneal macrophages derived
from four strains of mice [C57BL/6, BALB/c, double
knockout LMP7/MECL-1
-/-, and peroxisome prolifera-
tor-activated receptor-a
-/- (PPAR-a
-/-) knockout mice]
[3]. As several of these naturally-occurring compounds
appear to be non-toxic, we have become intrigued with
the concept of diet supplementation with these agents,
with the ultimate goal of preventing some of the damage
attributable to dysregulated inflammatory responses
associated with ageing. We have been greatly encour-
aged by our recent results demonstrating that serum
TNF-a and NO levels were significantly reduced in
chickens fed diets supplemented with either quercetin
or δ-tocotrienol, two naturally-occurring proteasome
inhibitors [5].
The main objective of the present study was to expand
upon our previous in vitro studies with mice and in vivo
studies with chickens [3,5]. Specifically, we were inter-
ested in evaluating the anti-inflammatory properties of
dietary supplementation with quercetin and δ-tocotrie-
nol in vivo in mice; dexamethasone, a well known anti-
inflammatory agent was used as a positive control. Con-
trol diet or diets supplemented with quercetin, δ-toco-
trienol, or dexamethasone were fed to young (4-week-
old) and senescent (42-week-old) male C57BL/6 mice
for 4 weeks (Figure 1). Thioglycolate-elicited peritoneal
macrophages were then collected from mice, stimulated
with LPS, and the capacity of these macrophages to gen-
erate inflammatory responses (e.g. TNF-a secretion and
NO production, TNF-a and iNOS gene expression,
microarray analysis) was assessed under a variety of
conditions. The results of the current study suggest that
these compounds could be used to prevent or slow
down the symptoms (fatigue, loss of memory and weak-
ness of body muscles) associated with the ageing process
in humans.
Materials and methods
Materials
Highly purified, deep rough chemotype LPS (Re LPS)
from E. coli D31m4 was prepared as described by Qure-
shi et al. [6]. Thioglycolate and dexamethasone were pur-
chased from Sigma-Aldrich (St. Louis, MO) and RNeasy
mini kit from QIAGEN Sciences (Germantown, MD,
USA). Quercetin was purchased from Alfa Aesar (John-
son Matthey Co. Lancaster, UK) and 50% δ-tocotrienol
was received as a gift from American River, MA, USA.
Animals
All mice used in this study received humane care in
compliance with principles of laboratory animals care
formulated by the National Society of Health Guide for
the Care and Use of Laboratory Animals by the US
National Institute of Health (NIH publication No 85-23,
revised 1996). The experimental procedures involving
animals were carefully reviewed and approved by the
Institutional Animal Care and Use Committee of
UMKC, MO, USA.
The 3-week-old and 41-week-old C57BL/6 male mice
were obtained from “The Jackson Laboratory” (Bar Har-
bor, ME, USA), and acclimatized to the new environ-
ment for seven days before the start of experimentation.
Mice were fed regular commercial mice diet with or
without supplements (see below) ad libitum and had
free access to water throughout the experiment. A 12 h
light (08 am) and 12 h dark (08 pm) cycle was main-
tained during the feeding period. The study was carried
out under a FDA IND number 36906 (USA).
Purification of δ-tocotrienol from purified 50% fraction of
annatto seeds
A commercial 50% purified fraction of δ-tocotrienol was
obtained from American River (Boston, MA), and sub-
jected to further purification as previously described [7].
The purity of δ-tocotrienol was established by high pres-
sure liquid chromatography (HPLC) against its stan-
dards as reported earlier [8].
Diet preparation and supplementation
Four groups of 3-week-old C57BL/6 male (3 mice/
group; n = 12) and 41-week-old C57BL/6 (n = 12) were
acclimatized for seven days to their new environment.
Mice (4-week-old and 42-week-old) were fed mice com-
mercial diet (CD; control group), or CD supplemented
Qureshi et al. Lipids in Health and Disease 2011, 10:239
http://www.lipidworld.com/content/10/1/239
Page 2 of 22with quercetin (100 ppm), δ-tocotrienol (100 ppm) or
dexamethasone (10 ppm) for 4 weeks. For diet supple-
mentation quercetin (200 mg), δ-tocotrienol (200 mg) or
dexamethasone (20 mg) were dissolved in 100 mL of
ethanol and added to 2 kg diet. The diet of the control
group was also mixed with 100 mL of ethanol. All mice
were weighed individually at the start and at the end of
the experiment.
Figure 1 Chemical structures of various compounds used in this study.
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course powder and mixed with 100 mL ethanol alone,
or 100 mL ethanol containing quercetin (100 ppm), δ-
tocotrienol (100 ppm) or dexamethasone (10 ppm);
ethanol was evaporated during mixing. Food and water
was provided to mice ad libitum.
Collection and LPS-stimulation of peritoneal macrophages
After being fed control diet or supplemented diets for 4
weeks, thioglycolate-elicited peritoneal macrophages
were prepared from each mouse as described previously
[9,10]. Thioglycolate-elicited peritoneal macrophages (1
×1 0
7/well) prepared from each group were challenged
with LPS alone (10 or 100 ng/well), LPS (10 ng/well)
plus IFN-b (50 U/well), LPS (10 ng/well) plus IFN-g (50
U/well), or medium alone (control group), and incu-
bated at either room temperature (NO), or 37°C (TNF-
a). After 4 h (LPS alone for the estimation of TNF-a),
or 18 hours (for NO assay, LPS alone or LPS plus IFN-b
or LPS plus IFN-g ) stimulated cells were centrifuged at
2,000 rpm for 20 min. The cells were then harvested for
RNA extraction, and the supernatants were stored in
glass vials at -70°C for subsequent measures of nitric
oxide (NO) and TNF-a levels.
Histological studies of liver samples after feeding various
compounds to 4-week-old or 42-week-old C57BL/6 male
mice for 4 weeks
After removing the thiogltcolate-elicited peritoneal
macrophages, mice were sacrificed and liver samples
were removed, stored in 10% formalin at -70°C until his-
tological analyses were carried out. After the tissues
were fixed in formalin, they were embedded with paraf-
f i na n dc u ti nt h es a g i t a lp l a n e .T h es e c t i o n sw e r e
stained by hematoxylin and eosin and examined by light
microscopy. A semi-quantitative evaluation of histologi-
cal analyses of these liver samples were carried out as
described previously [11]. Evaluation of samples were
carried out by two pathologists, unaware of the treat-
ments. Mean scores were assigned to each sample,
scored ranged from 0 (normal appearance) to 40 (very
severe impact). The means of the assigned values for
each group were reported.
Measurement of nitric oxide (NO) and TNF-a levels
NO levels were determined in thawed supernatants by
measuring the amount of nitrite, a stable metabolic pro-
duct of nitric oxide according to the reported procedure
[12]. The assay mixture contained medium (100 μL)
plus Griess reagent (100 μL) in round-bottom 96-well
tissue culture plates, and absorption was measured at
570 nm using a “Microplate Reader” (MR 5000; Dyna-
t e c hL a b s ,I n c .U S A ) .T h ea m o u n to fn i t r i t ew a s
determined by comparison of unknowns using a
NaNO2 standard curve. The NO detection limit is 0.20
nM [12].
TNF-a levels in thawed supernatants were determined
using the Quantikine M ELISA kit (R&D System, Min-
neapolis, MN, USA) according to manufacturer’s
instructions. The lower limit of detection for TNF-a in
this method is approximately, 5.0 pg/mL [9].
Detection of cell viability
The viability of peritoneal macrophages treated with
LPS, LPS + IFN-b,o rL P S+I F N - g were determined by
trypan blue dye exclusion or a quantitative colorimetric
assay with 3-(4, 5)-dimethylthiozol-2,5-diphenyl-tetrazo-
lium bromide (MTT) as described previously [13].
Measurement of TNF-a and iNOS gene expression levels
Thioglycolate-elicited peritoneal macrophages were pre-
pared from 8-week-old and 46-week-old C57BL/6 mice
after feeding control diet, (CD), quercetin (100 pmm), δ-
tocotrienol (100 ppm), or dexamethasone (10 ppm) sup-
plemented diets to 4-week-old and 42-week-old C57BL/
6m a l em i c ef o r4w e e k s .T h em a c r o p h a g e s( 1×1 0
7/
well in 100 μL) of both groups were adhered for 2 h in
the wells from control diet (CD), quercetin, δ-tocotrie-
nol, or dexamethasone treatments. After 2 h all the
wells were challenged with LPS (10 ng/well; 400 μL),
and incubated at room temperature for 4 h, then macro-
phages were harvested, and total cellular RNA was
extracted from each pellet with RNeasy mini kit (QIA-
GEN Sciences; Germantown, MD, USA) according to
the manufacturer’s instructions. Subsequent gene ana-
lyses for TNF-a and iNOS were performed after conver-
sion of purified RNA to DNA [14].
The cDNA for each treatment was amplified and ana-
lyzed by real-time polymerase chain reaction (RT-PCR)
to quantitate gene expression of TNF-a and iNOS by
using 1-step RT-PCR kit (Qiagen, Chatsworth, CA,
USA) according to the manufacturer’s instructions [14].
The viability of peritoneal macrophages treated with
LPS or LPS + various compounds were also determined
by trypan blue dye exclusion or a quantitative colori-
metric assay with 3-(4,5)-dimethylthiozol-2,5-diphenyl-
tetrazolium bromide (MTT) as described previously
[13].
Microarray analyses of RNA after treatment with LPS plus
control diet, quercetin, δ-tocotrienol or dexamethasone of
peritoneal macrophages from 8-week-old C57BL/6 male
mice
RNA isolation
Thioglycolate-elicited peritoneal macrophages from
C57BL/6 mice (8 week-old) were prepared. The
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of 12 well plates (1 × 10
7 cells/well in 1.0 mL medium)
for 2 h in the wells, then cells (macrophages) were
washed with medium three times. The cells were pre-
treated with medium, quercetin (40 μM), δ-tocotrienol
(20 μM) or dexamethasone (10 μM) for 1 h at room
temperature, followed by LPS 10 ng/well treatment for 4
h. After 4 h, total cellular RNA was isolated from trea-
ted and untreated cells (quercetin, δ-tocotrienol, and
dexamethasone) by using TRIzol reagent (Life Technol-
ogies, Gaithersburg, MD, USA), which was further puri-
f i e du s i n ga na f f i n i t yr e s i nc o l u m n( R N e a s ym i n ik i t ;
Qiagen, Chatsworth, CA, USA). Total RNA thus isolated
was converted to cDNA by use of the Superscript cDNA
synthesis kit (GIBCO-BRL, Gaithersburg, MD, USA).
Double-stranded cDNA was then purified by phase lock
gel (Eppendorf, Westbury, NY, USA) with phenol-
chloroform extraction [14].
Sample preparation, fragmentation, array hybridization,
and scanning
The purified cDNA was used as a template for the in
vitro transcription reaction for the synthesis of biotiny-
lated cRNA with the use of RNA transcript labeling
reagent (Affymetrix). This labeled cRNA was fragmented
and hybridized onto the Mouse Genome 430 2.0 array
as described [15]. Briefly, appropriate amounts of frag-
mented cRNA and control oligonucleotide B2 were
added along with control cRNA (BioB, BioC, BioD), her-
ring sperm DNA, and BSA to the hybridization buffer.
The hybridization mixture was heated at 99°C for 5 min
followed by incubation at 45°C for 5 min before the
sample was injected into the microarray. Then, the
hybridization was carried out at 45°C for 16 h with mix-
ing on a rotisserie at 60 rpm. After hybridization, the
solutions were removed, and the arrays were washed
and stained with streptavidin/phycoerythrin (Molecular
P r o b e s ,E u g e n e ,O R ) .A f t e rw a s h e s ,p r o b ea r r a y sw e r e
scanned using the Affymetrix Gene-Chip confocal scan-
ner at the Mayo Clinic (Rochester, MN), as described
previously [15].
Data analyses
Gene-Chip 3.0 (Affymetrix) was used to scan and quan-
titatively analyze the scanned image. Once the probe
array had been scanned, Gene-Chip software automati-
cally calculated intensity values for each probe cell and
made a presence or absence call for each mRNA. Algo-
rithms in the software used probe cell intensities to cal-
culate an average intensity for each set of probe pairs
representing a gene that directly correlated with the
amount of mRNA. Gene expression data were first
imported in the genespring program (Agilent, Palo Alto,
CA, USA), and the numbers were corrected for differ-
ences in the arrays. ALL numbers were corrected for
differences in the arrays and have been scaled to a factor
of 500 during the data extraction process. LPS/medium,
LPS + inhibitor/medium, or inhibitor/medium, log ratio
values were normalized to a scale of 0 (instead of 1,
which shows decimals) and expression values of upregu-
lated genes showed positive numbers, whereas the
downregulated genes showed negative numbers. These
ratios were imported into the Ingenuity Pathways Analy-
sis software (Ingenuity Systems, Mountain View, CA,
USA). Genes identified as statistically different in terms
of activation from control cells were analyzed and
mapped into different pathways.
Statistical Analysis
The overall analyses identified significant main effects
and interaction for all markers of various compounds
compared to control group and within the groups were
evaluated. Stat-View software (version 4.01) was used
for the analyses of treatment-mediated effects as com-
pared to control group (1992; Abacus Concepts, Berke-
ley, CA, USA). Treatment-mediated differences in
various inflammatory markers variables were identified
using a two-way analysis of variance (ANOVA). When
the F test indicated a significant effect, the differences
between the means were analyzed by a Fisher’sP r o -
tected Least Significance Difference (LSD) test. Data
were reported as means ± SD in text and Tables. The
statistical significance level was set at 5% (P < 0.05).
Results
At the start of the experiment, four groups of 4-week-
old and 42-week-old mice were fed control diet alone or
three experimental diets (control diet supplemented
with quercetin. δ-tocotrienol, or dexamethasone) for 4
weeks. At the end of the feeding period, the results of
8-week-old and 46-week-old mice were compared,
described and discussed throughout this paper.
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on body weight gain
The first question that we wanted to answer was
whether supplementation of commercial diet (control
diet) with quercetin, δ-tocotrienol, or dexamethasone
would affect body weight gains in either age group of
male C57BL/6 mice. Young (4-week-old) and senescent
(42-week-old) C57BL/6 male mice were fed control diet
or control diet supplemented with quercetin (100 ppm),
δ-tocotrienol (100 ppm), or dexamethasone (10 ppm)
for 4 weeks, and body weight gains were determined
after this 4 week feeding period. As shown in Table 1,
when fed control diet alone, the weight of 8-week-old
and 46-week-old mice increased by an average of 29%
and 23%, respectively, over the 4 week period of feeding.
Mice whose diet was supplemented with dexametha-
sone, gained significantly less weight than mice fed
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week-old mice, respectively) (Table 1). These results
confirm our earlier findings in which feeding a diet sup-
plemented with dexamethasone to chickens significantly
reduced weight gain (> 75% reduction; P <0 . 0 5 )c o m -
pared to control diet [5]. Mice whose diets were supple-
mented with quercetin or δ-tocotrienol had weight gains
that did not differ significantly from mice fed control
diet. Overall consumption of food by mice in each
group was similar, ranging between 245 and 256 g over
the four week period of feeding, so dietary supplementa-
tion did not appear to have a substantial effect on food
intake. Thus, the results of these studies demonstrate
that diet supplementation with either quercetin or δ-
tocotrienol does not have a significant impact on body
weight gain (Table 1).
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on histological analyses of
liver samples
Mice fed diets supplemented with dexamethasone had
reduced weight gains compared to mice fed δ-tocotrie-
nol or quercetin supplemented diets, or control diets
(Table 1). Despite these differences, mice fed diets sup-
plemented with dexamethasone were active, and there
were no obvious abnormalities in physical appearance or
behavior. As a preliminary assessment of potential toxi-
cities attributable to the diet supplements, we conducted
a histological analysis of liver samples from mice fed
control and supplemented diets. Semi-quantitative histo-
logical analysis of these liver samples was carried out as
described previously [11]. Mean scores (MS) were
assigned for each variable for each sample, with scores
ranging from 0 (normal appearance) to 40 (very severe
impact)
Analysis of livers from the control groups of 8-week-
old and 46-week-old mice showed peliosis (MS = 15),
lymphoplasmacytic clusters (MS = 15), nuclear dysplasia
(MS = 15) and nuclear retreat (MS = 15) (Table 2; Fig-
ure 2). Small or large lymphoplasmacytic clusters were
found in liver samples of quercetin (MS = 20) and δ-
tocotrienol (MS = 20) fed mice. Liver samples of 8-
week-old dexamethasone fed mice showed several
pathological alterations, such as the presence of Coun-
cilman body (MS = 40), microvesicular steatosis (MS =
20), nuclear dysplasia (MS = 20), and nuclear retraction
globules (MS = 20). Liver samples of 46-week-old dexa-
methasone fed mice showed large lymphoplasmacytic
clusters (MS = 20), Councilman body (MS = 15),
nuclear retreat (MS = 15) and dysplasia (MS = 15) (Fig-
ure 2). Based on the presence of a large number of
councilman body (MS = 40), nuclear retreat (MS = 20),
and other abnormalities in liver samples of dexametha-
sone fed mice, it appears that greater toxicity is asso-
ciated with diet supplementation with dexamethasone
compared to diet supplementation with either quercetin
or δ-tocotrienol (Table 2, Figure 2).
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on nitric oxide (NO)
production by LPS-stimulated macrophages
We have previously reported that peritoneal macro-
phages derived from C57BL/6 female mice treated in
vitro with quercetin, δ-tocotrienol, or dexamethasone
have depressed NO responses to LPS-stimulation [3]. As
enhanced NO production associated with ageing has
been implicated in a variety of age-related diseases [1],
we were extremely interested in determining whether
macrophages derived from mice whose diets were sup-
plemented with quercetin, δ-tocotrienol, or dexametha-
sone would have similarly depressed NO responses to
LPS-stimulation. Mice were fed control diet or diets
supplemented as described above. After 4 weeks, mice
were sacrificed, and thioglycolate-elicited peritoneal
macrophages were collected and challenged with LPS
(10 ng or 100 ng/well) for 18 h, and NO was measured
in cell culture supernatants.
First, we wanted to determine whether age affected
the ability of mice to respond to LPS as measured by
NO production. As shown in Figure 3A and 3B, 46-
week-old mice had a significantly more robust NO
response to LPS-stimulation than 8-week-old mice as
Table 1 Effects of various compounds on weight gain of 8-week-old and 46-week-old C57BL/6 male mice after feeding
for four weeks
1
NO Weight gain in gm (8-week-old) Weight gain in gm (46-week-old)
C57BL/6 male mice
2 Pre-Feeding Post-Feeding Pre-Feeding Post-Feeding
1 Control Diet (CD) 21.43 ± 2.25
a (100)
3 27.54 ± 2.56
b (129)
3 30.32 ± 2.63
a (100)
3 37.31 ± 3.46
b (123)
3
2 CD + Quercetin (100 ppm) 22.72 ± 2.42
a (100) 27.92 ± 2.37
b (123) 28.47 ± 2.52
a (100) 36.62 ± 3.76
b (129)
3 CDA + δ-Tocotrienol (100 ppm) 20.25 ± 2.26
a (100) 26.42 ± 2.51
b (130) 30.33 ± 2.64
a (100) 37.32 ± 3.38
b (123)
4 CD + Dexamathasone (10 ppm) 21.47 ± 2.62
a (100) 23.53 ± 2.41
a (110) 31.58 ± 3.22
a (100) 33.61 ± 3.21
a (106)
1Each compound (200 mg or 20 mg) was dissolved in ethanol (100 mL) and mixed with powder commercial diet (2 kg).
2Data are means ± SD, n = 3 mice per group.
3Percentage of gain in weight in each group compared to respective control group are in parenthesis.
a-bValues in a row not sharing a common superscript letter are significantly different at P < 0.05.
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μM] for 10 ng L P S ,a n d9v s1 3[ 3 3 . 9 0v s5 8 . 5 5μM] for
100 ng LPS). When stimulated with 10 ng LPS, NO pro-
duction by macrophages from 46-week-old mice was
55% (P < 0.05) higher than that of 8-week-old mice fed
control diet. With 100 ng LPS, NO production was 73%
(P < 0.02) higher in 46-week-old vs. 8-week-old mice
fed control diet (Figure 3A). These results strongly sup-
port and confirm earlier observations that senescence
enhances the NO responses of murine macrophages to
LPS-stimulation [4].
Next, we were interested in determining the extent to
which diet supplementation with quercetin, δ-tocotrie-
nol, or dexamethasone might suppress NO production
in response to LPS. Compared to mice fed control diet,
macrophages from mice fed control diet supplemented
with dexamethasone produced significantly less NO (P
< 0.02) when stimulated with either 10 ng (32% and 59%
reduction in NO production by 8-week-old and 46-
week-old mice, respectively), or 100 ng LPS (48% and
62% reduction in NO production, respectively) (Figure
3B). Although the suppressive effect of diet supplemen-
tation with dexamethasone on NO production was
observed in both young and senescent mice, it was
more pronounced in senescent compared to young
mice.
Diet supplementation with quercetin and δ-tocotrienol
produced results comparable to dexamethasone (Figure
3A,B). NO production by macrophages stimulated with
either 10 ng or 100 ng LPS was significantly (P < 0.02)
reduced in macrophages derived from mice fed control
diet plus quercetin or control diet plus δ-tocotrienol
compared to those derived from mice fed control diet
alone. Again, the suppressive effects of diet supplemen-
tation on NO production was observed in both young
and senescent mice, but was more pronounced in senes-
cent compared to young mice (Figure 3B). Thus, diet
supplementation with quercetin, δ-tocotrienol, or dexa-
methasone significantly reduced the ability of LPS-sti-
mulated macrophages to produce NO, and these
suppressive effects were more pronounced in senescent,
compared to young, mice (Figure 3B).
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on nitric oxide (NO)
production by macrophages stimulated with both LPS +
interferon-b (IFN-b)
Endogenous b-interferon (IFN-b) is an essential cofactor
in LPS-induced NO production by macrophages, and
exogenous IFN-b has been shown to enhance NO pro-
duction by LPS-stimulated macrophages from both
young and senescent mice [4]. Thus, the experiments
described above were essentially duplicated, except that
macrophages were stimulated with either LPS alone (10
ng)o rL P S( 1 0ng)p l u sI F N - b (50 U/well) to determine
the effects of diet supplementation with quercetin or δ-
tocotrienol on nitric oxide (NO) production by macro-
phages stimulated with both LPS and IFN-b.
Data presented in Figure 4A,B are consistent with
those presented in Figure 3. When fed a control diet,
46-week-old mice had a significantly more robust NO
response (43.92 μM; column 5, Figure 4A) to LPS-sti-
mulation than 8-week-old mice (28.84 μM; column 1,
Figure 4A). As expected (Figure 4A), macrophages
derived from both young and senescent mice fed control
diet, produced significantly (P < 0.02) more NO when
Table 2 Effects of various compounds after feeding C57BL/6 of 8-week-old and46-week-old C57BL/6 male mice on
histological analyses of liver samples
1
# SET I (8-week-old) Summary
1 Control diet (CD) Peliosis, nuclear dysplasia and nuclear retreat.
2 CD + Quercetin Small & large lymphoplasmacytic clusters.
3C D + δ-Tocotrienol Large lymphoplasmacytic (LP) cluster, Councilman body.
4C D +
Dexamethasone
Councilman body, nuclear retreat and dysplasia, microvesicular steatosis, large lymphoplasmacytic (LP) cluster, closed
sinusoids, cytoplasmic condensation.
SET II (46-week-
old)
Summary
5 Control diet (CD) LP clusters, nuclear Retreat and dysplasia, microvesicular steatosis.
6 CD + Quercetin Coucilman body, nuclear dysplasia and nuclear retreat.
7C D + δ-Tocotrienol Small & large Lymphoplasmacytic clusters.
8C D +
Dexamethasone
Small LP cluster, Councilman body, nuclear Retreat and dysplasia cytoplasmic condensation.
1Young (4-week-old) and senescent (42-week-old) C57BL/6 male mice were fed control diet or control diet supplemented with quercetin (100 ppm), δ-tocotrienol
(100 ppm), or dexamethasone (10 ppm) for 4 weeks. After 4 weeks of feeding, thioglycolate-elicited peritoneal macrophages were prepared [9,10], then mice
were sacrificed, and liver samples were removed, stored in 10% formalin at -70°C until histological analyses were carried out. After the liver tissues were fixed in
formalin, they were embedded in the paraffin, and cut in the sagital plane. The sections were stained by hematoxylin and eosin, and examined under light
microscopy. A semi-quantitative evaluation of histological analyses were carried out as described previously [11]. Mean scores (MS) were assigned to each
sample, scored ranged from 0 (normal appearance) to 40 (very severe impact). The means of the assigned values for each group were reported
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Page 7 of 22Figure 2 Effects of dietary supplementation with various compounds on histological analyses of livers of 8-week-old and 46-week-old
C57BL/6 male mice: The scan 1-8 shows the histological evaluation of representative liver sections from mice fed commercial diets with and
without quercetin (100 ppm), δ-tocotrienol (100 ppm), and dexamethasone (10 ppm) to 4-week-old and 42-week-old male C57BL/6 mice for 4
weeks. The livers of each mouse was processed as described in experimental section. A = 8-week-old mice: 1. control; 2. quercetin; 3. δ-
tocotrienol; 4. dexamethasone; B = 46-week-old mice, 5. control; 6. quercetin; 7. δ-tocotrienol; 8. dexamethasone.
Qureshi et al. Lipids in Health and Disease 2011, 10:239
http://www.lipidworld.com/content/10/1/239
Page 8 of 22Figure 3 Effects of dietary supplementation with various compounds on the production of nitric oxide (μM) by LPS-stimulated
thioglycolate-elicited peritoneal macrophages. 4-week-old and 42-week-old C57BL/6 male mice were fed control diet or control diets
supplemented with quercetin, δ-tocotrienol or dexamethasone for 4 week. After this, thioglycolate-elicited peritoneal macrophages were
collected, adhered to the bottom of 12 well plates (1×10
7 cells/well in 1.0 mL medium) for 4 h, then washed with medium three times. Cells
were then treated with LPS (10 ng/well or 100 ng/well) for 18 h at room temperature, the mixtures were centrifuged at 2000 rpm for 20 min,
and supernatants were collected, and stored at -70°C for subsequent analysis of NO using Griess reagent [12]. Cell viability exceeded 95% in all
experiments [13]. Data represent means ± SD; n = 3 mice per group with triplicate analysis of each sample. Values in columns with different
symbols differ at P < 0.05. Treatments 1 - 16 correspond to: 1 - 4 = 8-week-old or 5 - 8 = 46-week-old mice treated with 10 ng/well LPS; 9 - 12
= 8-week-old or 13 - 16 = 46-week-old mice treated with 100 ng/well LPS. CD = control diet; Quer = quercetin; Trie = δ-tocotrienol; Dexa =
dexamethasone.
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Page 9 of 22Figure 4 Effects of dietary supplementation with quercetin, δ-tocotrienol, or dexamethasone on the production of nitric oxide by
thioglycolate-elicited peritoneal macrophages stimulated with LPS-plus IFN-b</ττ>. 4-week-old and 42-week-old C57BL/6 male mice were
fed control diet (CD) or control diet supplemented with quercetin, δ-tocotrienol or dexamethasone for 4 week. After this, thioglycolate-elicited
peritoneal macrophages were collected, adhered to the bottom of 12 well plates (1×10
7 cells/well in 1.0 mL medium) for 4 h, then washed with
medium three times. Cells were treated with LPS (10 ng/well) or LPS (10 ng + IFN-b 50 U/well) for 18 h at room temperature, mixtures were
centrifuged at 2000 rpm for 20 min. The supernatants were collected, and were assayed for production of NO by using Griess reagent [12]. Cell
viability exceeded 95% in all experiments [13]. Data represent means ± SD; n = 3 mice per group, with triplicate analysis of each sample. Values
in columns with different symbols differ at P < 0.05. Treatments 1 - 16 correspond to: 1 - 4 = 8-week-old mice or 5 - 8 = 46-week-old mice
treated with 10 ng/well LPS; 9 - 12 = 8-week-old mice or 13 - 16 = 46-week-old mice treated with 10 ng LPS plus + 50 U/well IFN-b.C D=
control diet; Quer = quercetin; Trie = δ-tocotrienol; Dexa = dexamethasone.
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Page 10 of 22stimulated with both LPS and IFN-b [columns 9 (56.81
μM) and 13 (93.61 μM) for young and senescent mice,
respectively] compared to stimulation with LPS alone
[column 1 (28.84 μM) and column 5 (43.92 μM) for
young and senescent mice, respectively]. The production
of NO by macrophages from senescent mice stimulated
with both LPS and IFN-b was particularly robust. Diet
supplementation with quercetin, tocotrienol, or dexa-
methasone significantly suppressed NO production by
macrophages stimulated with either LPS alone, or LPS
plus IFN-b. This suppression was observed with macro-
phages derived from both young and senescent mice,
but the extent of suppression (67-77%; columns 14-16)
was greatest in LPS plus IFN-b stimulated macrophages
derived from senescent mice (Figure 4A,B).
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on nitric oxide (NO)
production by macrophages stimulated with both LPS +
interferon-g (IFN-g)
Interferon-g (IFN-g) is a potent macrophage activator
that synergizes with a variety of other macrophage acti-
vators to enhance NO production, and exogenous IFN-g
has been shown to enhance NO production by LPS sti-
mulated macrophages from both young and senescent
mice [4]. Thus, the experiments described above were
essentially duplicated, except that macrophages were sti-
mulated with either LPS alone (10 ng)o rL P S( 1 0ng)
plus IFN-g (50 U/well) to determine the effects of diet
supplementation with quercetin, or δ-tocotrienol on
nitric oxide (NO) induction by macrophages stimulated
with both LPS and IFN-g.
Data presented in Figure 5A,B are consistent with
those presented in Figures 3 and 4. When fed a control
diet, 46-week-old mice had a significantly (P <0 . 0 5 )
more robust NO response (33.78 μM; Figure 5A, col-
umn 5) to LPS-stimulation than 8-week-old mice (22.29
μM; Figure 5A, column 1). As expected (Figure 5A),
macrophages derived from both young and senescent
mice fed control diet, produced significantly (P <0 . 0 2 )
more NO when stimulated with both LPS and IFN-b
[columns 9 (64.18 μM) and 13 (118.72 μM) for young
and senescent mice, respectively] compared to stimula-
tion with LPS alone [columns 1 (22.29 μM) and 5 (33.78
μM) for young and senescent mice, respectively]. NO
production by macrophages from senescent mice stimu-
lated with both LPS and IFN-g was particularly robust.
Diet supplementation with dexamethasone, quercetin, or
δ-tocotrienol significantly suppressed NO production by
macrophages stimulated with either LPS alone, or LPS
plus IFN-g. This suppression was observed with macro-
phages derived from both young and senescent mice,
but the extent of suppression (62-72%; columns 14-16)
was greatest in LPS plus IFN-g stimulated macrophages
derived from senescent mice (Figure 5A,B)
Effects of dietary supplementation of quercetin, δ-
tocotrienol, or dexamethasone on TNF-a secretion by
LPS-stimulated macrophages
TNF-a is among the earliest and most important pro-
inflammatory cytokines produced in response to a vari-
ety of inflammatory stimuli. We have previously demon-
strated that proteasome inhibitors can suppress TNF-a
secretion by LPS-stimulated macrophages in vitro,s ow e
opted to determine the extent to which diet supplemen-
tation with quercetin, δ-tocotrienol, or dexamethasone
might suppress TNF-a secretion in response to LPS [4].
Mice were fed the same control and supplemented diets
described in the previous sections. After 4 weeks, thio-
glycolate-elicited peritoneal macrophages were collected
and challenged with 100 ng/well LPS for 4 h, and TNF-
a was measured in cell culture supernatants. In contrast
to the results with NO, age did not have a significant
effect on TNF-a secretion by LPS-stimulated macro-
phages; TNF-a levels were comparable in supernatants
of LPS-stimulated peritoneal macrophages from 8-week-
old (2,980 pg/mL) and 46-week-old (3,241 pg/mL) mice
fed control diet (Figure 6A,B). LPS-stimulated macro-
phages from both young and senescent mice fed control
diet supplemented with quercetin, δ-tocotrienol, or dex-
amathasone, however, produced significantly less (P <
0.05) TNF-a than macrophages from mice fed control
diet (Figure 6A,B). Control diet supplementation with
dexamathasone, quercetin, or δ-tocotrienol suppressed
TNF-a s e c r e t i o nb y3 0 % ,2 0 % ,a n d1 6 %r e s p e c t i v e l y ,i n
8-week-old mice, and by 36%, 23%, and 14%, respec-
tively in 46-week-old mice. The extent of the reduction
in TNF-a secretion was comparable in both age groups
(Figure 6A,B). Thus, diet supplementation with querce-
tin, δ-tocotrienol, or dexamethasone significantly
reduces the ability of LPS-stimulated macrophages to
produce TNF-a (Figure 6A,B).
Effects of diet supplementation with quercetin, δ-
tocotrienol, or dexamethasone on expression levels of
TNF-a and iNOS genes in LPS-stimulated macrophages
The results presented above collectively demonstrate that
increasing age enhances NO production, and diet supple-
mentation with quercetin, δ-tocotrienol, or dexametha-
sone suppresses production of NO and TNF-a by LPS-
stimulated macrophages from both young and senescent
mice. The next series of experiments were designed to
determine whether the changes observed in NO and
TNF-a production attributable to age or diet supplemen-
tation were associated with comparable changes in
mRNA expression levels for the TNF-a and iNOS genes.
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Page 11 of 22Figure 5 Effects of dietary supplementation with quercetin, δ-tocotrienol, or dexamethasone on the production of nitric oxide by
thioglycolate-elicited peritoneal macrophages stimulated with LPS-plus IFN-g</ττ>. 4-week-old and 42-week-old C57BL/6 male mice were
fed control diet (CD) or control diet supplemented with quercetin, δ-tocotrienol or dexamethasone for 4 week. After this, thioglycolate-elicited
peritoneal macrophages were collected, adhered to the bottom of 12 well plates (1×10
7 cells/well in 1.0 mL medium) for 4 h, then washed with
medium three times. Cells were treated with LPS (10 ng/well) or LPS 10 ng + IFN-g 50 U/well) for 18 h at room temperature, mixtures were
centrifuged at 2000 rpm for 20 min. The supernatants were collected and assayed for production of NO by using Griess reagents [12]. Cell
viability exceeded 95% in all experiments [13]. Data represent means ± SD; n = 3 mice per group, with triplicate analysis of each sample. Values
in columns with different symbols differ at P < 0.05. Treatments 1 - 16 correspond to: 1 - 4 = 8-week-old mice or 5 - 8 = 46-week-old mice
treated with 10 ng/well LPS; 9 - 12 = 8-week-old mice or 13 - 16 = 46-week-old mice treated with 10 ng LPS plus + 50 U/well IFN-g.C D=
control diet; Quer = quercetin; Trie = δ-tocotrienol; Dexa = dexamethasone.
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Page 12 of 228-week-old C57BL/6 mice (LPS 100 ng).        46-week-old C57BL/6 mice (LPS 100 ng).
Figure 6 Effects of dietary supplementation with various compounds on the secretion of TNF-a by thioglycolate-elicited peritoneal
macrophages stimulated with LPS. 4-week-old and 42-week-old C57BL/6 male mice were fed control diet or control diet supplemented with
quercetin, δ-tocotrienol or dexamethasone for 4 week. After this, thioglycolate-elicited peritoneal macrophages were collected, adhered to the
bottom of 12 well plates (1×10
7 cells/well in 1.0 mL medium) for 4 h, then washed with medium three times. Then cells were treated with LPS
(100 ng/well), and incubated at 37°C in 5% CO2 for 4 h [9]. Supernatants were used to carry out TNF-a assays by ELISA. Data are means ± SD; n
= 3 mice per group, with triplicate analysis of each sample. Values in columns with different symbols differ at P < 0.05. The treatments 1 - 8
correspond to: 1 - 4 = 8-week-old mice or 5 - 8 = 46-week-old mice treated with 100 ng LPS. CD = control diet; Quer = quercetin; Trie = δ-
tocotrienol; Dexa = dexamethasone.
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Page 13 of 22Young (4-week-old) and senescent (42-week-old)
C 5 7 B L / 6m a l em i c ew e r ef e dc o n t r o ld i e to rc o n t r o l
diets supplemented with quercetin (100 ppm), δ-toco-
trienol (100 ppm), or dexamethasone (10 ppm) for 4
weeks. After 4 weeks, 8-week-old and 46-week-old mice
were sacrificed, and thioglycolate-elicited peritoneal
macrophages were prepared, and challenged with LPS
(10 ng/well) for 4 h. Cells were harvested, total cellular
RNA extracted, and targeted genes were amplified and
analyzed by RT-PCR to determine relative expression
levels. As shown in Table 3 and Figure 7, mRNA levels
for TNF-a were roughly comparable in LPS stimulated
macrophages from 8-week-old and 46-week-old mice
fed control diet. In contrast, mRNA levels for iNOS
were substantially higher in LPS- stimulated macro-
phages from 46-week-old compared to 8-week-old mice
fed control diet.
LPS-stimulated macrophages from 8-week-old and 46-
week-old mice whose diets were supplemented with
quercetin, δ-tocotrienol, or dexamethasone had reduced
levels of mRNA for both the iNOS and TNF-a genes,
compared to macrophages from mice fed control diet.
Thus, results at the gene expression level for iNOS and
TNF-a were entirely consistent with results of NO pro-
duction and TNF-a secretion by LPS-stimulated macro-
phages. iNOS mRNA levels and NO production were
higher in LPS-stimulated macrophages from senescent
compared to young mice. In contrast, TNF-a RNA and
secretion of TNF-a protein by LPS-stimulated macro-
phages did not appear to be affected by age. Diet sup-
plementation with dexamethasone, quercetin, or δ-
tocotrienol for 4 weeks resulted in decreased mRNA
expression levels and decreased secretion of TNF-a pro-
tein and NO by LPS-stimulated macrophages from both
senescent and young mice (Table 3).
Effects of quercetin, δ-tocotrienol, or dexamethasone on
gene transcription in LPS-stimulated thioglycolate-elicited
peritoneal macrophages as assessed by microarray
analyses
The results of experiments presented above demon-
strated that production of NO and TNF-a,a n dt r a n -
scription of iNOS and TNF-a genes, was reduced in
both young and senescent mice fed diets supplemented
with quercetin, δ-tocotrienol, or dexamethasone for 4
weeks. These results were further supported by microar-
ray analyses of RNA purified from LPS-stimulated thio-
glycolate-elicited peritoneal macrophages of 8-week-old
C57BL/6 male mice pretreated with quercetin, δ-toco-
trienol, or dexamethasone for 1 h, followed by LPS 10
ng/treatment for 4 h. Total cellular RNA was extracted
as described in the experiment section. Extracted RNA
was converted to cDNA according to Affymetrix expres-
sion analysis technical manual.
The data in Tables 4, 5, and 6 represent the number
of genes modulated by LPS; and LPS plus quercetin,
dexamethasone and δ-tocotrienol; and quercetin, dexa-
methasone, and δ-tocotrienol alone. The LPS-modulated
genes have been categorized with respect to functions,
that is, specifically immune response, cell to cell signal-
ing, cellular growth and proliferation, inflammatory dis-
eases, respiratory diseases, immunological diseases,
cancer, hepatic system diseases, cardiovascular system,
lipid metabolism, neurological diseases, and gene
expression. It is clear from these Tables that several
functions are affected by treatment with LPS, and LPS
plus quercetin, dexamethasone or δ-tocotrienol, or inhi-
bitors alone. When the LPS-modulated genes were also
categorized with respect to canonical pathways, such as
C21-steroid hormone metabolism, Notch signaling, sero-
tinin receptor signaling, retinol metabolism, toll-like
Table 3 Effects of various compounds on the gene expression of TNF-a and iNOS in LPS-stimulated thioglycolate-
elicited peritoneal macrophages derived from 8-week-old and 46-week-old C57BL/6 male mice after feeding for 4
weeks
1.
8-week-old vs 46-week-old RT-PCR (8-wk-old) data
2 RT-PCR (46-wk-old) data
2
NO Gene Expression Gene Expression
C57BL/6 Male Mice TNF-a iNOS TNF-a iNOS
1 Media + Macrophages (MM) 0 0 0 0
2 MM + LPS, 10.0 ng/mL (A) 0.35 (100)*
3 0.41 (100)
3 0.38 (100)
3 0.69 (100)
3
3 A + Quercetin (100 ppm) 0.26 (74) 0.29 (71) 0.29 (76) 0.47 (68)
4A + δ-Tocotrienol (100 ppm) 0.24 (69) 0.22 (54) 0.20 (53) 0.28 (41)
5 A + Dexamethasone (10 ppm) 0.20 (57) 0.15 (37) 0.27 (71) 0.20 (29)
*Control groups 8-week-old vs 46-week-old
TNF-a 0.35 (100) 0.38 (109)
iNOS 0.41 (100) 0.69 (168)
1The assay mixture (A; contains 0.2% dimethyl sulfoxide = DMSO) was treated with LPS (10.0 ng/well) for 4 h.
2Total RNA was extracted using RNAeasy mini Kit.
3Percentage of control ratio, based on MM + LPS 10.0 ng/well.
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Figure 7 Effects of dietary supplementation of various compounds on the gene expression of iNOS and TNF-a in LPS-stimulated
thioglycolate-elicited peritoneal macrophages derived from 8-week-old and 46-week-old C57BL/6 male mice after feeding for 4
weeks. 4-week-old and 42-week-old C57BL/6 male mice were fed control diet or control diet supplemented with quercetin, δ-tocotrienol or
dexamethasone for 4 week. After this, thioglycolate-elicited peritoneal macrophages were collected, adhered to the bottom of 12 well plates
(1×10
7 cells/well in 1.0 mL medium) for 4 h, then washed with medium three times. The cells were treated with LPS (10.0 ng/well) for 4 h, and
the purified RNA of each mouse was subjected to RT-PCR analyses, as described in the experimental section. The top rows in Figure 7,
correspond to b-Actin, middle rows, iNOS and bottom rows, TNF-a (8-week-old mice, 1-12, and 46-week-old mice, 13 - 24).8-week-old mice,f or
iNOS (middle row, 1-12), and TNF-a (bottom row, 1-12):1. Medium + macrophages = cells, 2. Cells + LPS 10 ng/well, 3. Cells + LPS 1 ng/well;
4. Medium + macrophages = cells, 5. Cells + LPS 10 ng/well + quercetin, 6. Cells + LPS 1 ng/well + quercetin; 7. Medium + macrophages =
cells, 8. Cells + LPS 10 ng/well + δ-tocotrienol, 9. Cells + LPS 1 ng/well + δ-tocotrienol; 10. Medium + macrophages = cells, 11. Cells + LPS 10
ng/well + dexamethasone 12. Cells + LPS 1 ng/well + dexamethasone.46-week-old mice,f or iNOS (second row, 13-24), and TNF-a (third
row, 13-24):13. Medium + macrophages = cells, 14. Cells + LPS 10 ng/well, 15. Cells + LPS 1 ng/well; 16. Medium + macrophages = cells, 17.
Cells + LPS 10 ng/well + quercetin, 18. Cells + LPS 1 ng/well + quercetin; 19. Medium + macrophages = cells, 20. Cells + LPS 10 ng/well + δ-
tocotrienol, 21. Cells + LPS 1 ng/well + δ-tocotrienol; 22. Medium + macrophages = cells, 23. Cells + LPS 10 ng/well + dexamethasone 24. Cells
+ LPS 1 ng/well + dexamethasone.
Table 4 Effects of LPS, LPS + quercetin, and quercetin on the levels of gene expression, and biological functions in
macrophages of8-week-old C57BL/6 male mice
1
Regulation Regulation Regulation
# Functions LPS Up Down LPS + Quer Up Down Quer Up Down
1 Immune response 182 130 52 124 84 40 39 93 0
2 Cell to cell signaling 124 86 38 136 78 58 41 43 7
3 Cellular growth & proliferation 74 54 20 99 61 38 36 22 14
4 Inflammatory diseases 74 53 21 88 61 27 24 12 3
5 Respiratory diseases 44 34 10 42 31 11 27 42 3
6 Immunological diseases 39 35 4 37 26 11 9 63
7 Cancer 34 25 9 42 28 14 13 94
8 Hepatic system diseases 26 23 3 5 5
9 Cardiovascular system 18 14 4 44 33 11 10 82
10 Carbohydrate Metabolism 8 53 13 11 2
11 Lipid metabolism 7 7 53 36 17 39 24 15
12 Neurological Diseases 6 51 34 29 5 4 4
13 Free-radical scavenging 5 41 4 31
14 Gene expression 4 4 7 61
Total 645 479 166 724 479 245 246 94 152
LPS = Lipopolysaccharide; Quer = Quercetin.
1The data in this Table represents the expression of a number of genes modulated by various treatments; The macrophages were treated with LPS alone (10 ng/
well), LPS (10 ng/well) + quercetin (40 μM), or quercetin (40 μM) alone as described in the experimental section. Total RNA was extracted from the treated cells
and their gene expression profiles compared with the control (LPS), and untreated cells. The values here been corrected for differences in the arrays. The gene
expression values are reported as average normalization log ratios. A data containing gene identifiers and their corresponding expression values were uploaded
as an Excel spreadsheet using the template provided in the Ingenuity Pathways Analysis program. Similar conditions were used for data provided in Tables 8, 9,
and 10.
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Page 15 of 22Table 5 Effects of LPS, LPS + δ-tocotrienol, and δ-tocotrienol on the levels of gene expression, and biological functions
in macrophages of 8-week-old C57BL/6 male mice
1.
Regulation Regulation Regulation
# Functions LPS Up Down LPS + Trie Up Down Trie Up Down
1 Immune response 182 130 52 132 80 52 50 40 10
2 Cell to cell signaling 124 86 38 97 46 51 52 40 12
3 Cellular growth & proliferation 74 54 20 55 42 13 32 18 14
4 Inflammatory diseases 74 53 21 9 545 5
5 Respiratory diseases 44 36 8 5 5
6 Immunological diseases 39 33 6 10 644 13
7 Cancer 34 25 9 29 22 7 17 12 5
8 Hepatic system diseases 26 23 3 8 713 21
9 Cardiovascular system 18 14 4 33 27 6 6 42
10 Carbohydrate Metabolism 8 53 14 59
11 Lipid metabolism 7 7 45 35 10 49 34 15
12 Neurological Diseases 6 51 26 24 2 4 4
13 Free-radical scavenging 5 41 4 31
14 Gene expression 4 4 23 19 4 3 3
Total 645 479 166 481 318 163 234 171 63
LPS = Lipopolysaccharide; Trie = δ-Tocotrienol.
1The data in this Table represents the expression of a number of genes modulated by various treatments; macrophages were treated with LPS alone (10 ng/well),
LPS (10 ng/well) + δ-tocotrienol (20 μM), or δ-tocotrienol (20 μM) alone as described in the experimental section. Total RNA was extracted from the treated cells
and their gene expression profiles compared with the control (LPS), and untreated cells. The values here have been corrected for differences in the arrays. The
gene expression values are reported as average normalization log ratios. A data set containing gene identifiers and their corresponding expression values were
uploaded as an Excel spreadsheet using the template provided in Ingenuity Pathways Analysis Program. Similar conditions were used for data provided in Tables
8, 9, 10.
Table 6 Effects of LPS, LPS + dexamethasone, and dexamethasone on levels of gene expression, and biological
functions in macrophages of 8-week-old C57BL/6 male mice
1.
Regulation Regulation Regulation
# Functions LPS Up Down LPS + Dexa Up Down Dexa Up Down
1 Immune response 182 130 52 126 77 49 97 53 44
2 Cell to cell signaling 124 86 38 119 64 55 70 24 46
3 Cellular growth & proliferation 74 54 20 84 38 46 18 21 6
4 Inflammatory diseases 74 53 21 83 58 25 17 11 6
5 Respiratory diseases 44 36 8 28 24 4 17 11 6
6 Immunological diseases 39 33 6 16 12 4
7 Cancer 34 25 9 45 34 11
8 Hepatic diseases 26 23 3 35 31 4
9 Cardiovascular system 18 14 4 20 13 7 14 10 4
10 Carbohydrate Metabolism 8 53
11 Lipid metabolism 7 7 55 36 19 27 25 2
12 Neurological Diseases 6 51 26 23 3
13 Free-radical scavenging 5 41 5 23
14 Gene expression 4 4 25 21 4 18 16 2
Total 645 479 166 662 431 231 283 154 129
LPS = lipopolysaccharide; Dexa = Dexamethasone.
1The data in this Table represents the expression of a number of genes modulated by various treatments; The macrophages were treated with LPS alone (10 ng/
well), LPS (10 ng/well) + dexamethasone (10 μM), or dexamethasone (10 μM) alone as described in the experimental section. Total RNA was extracted from the
treated cells and their gene expression profiles compared with the control (LPS), and untreated cells. The values here been corrected for differences in the arrays.
The gene expression values are reported as average normalization log ratios. A data containing gene identifiers and their corresponding expression values were
uploaded as an Excel spreadsheet using the template provided in the Ingenuity Pathways Analysis program. Similar conditions were used for data provided in
Tables 8, 9, and 10.
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Page 16 of 22receptor signaling, and bile acid synthesis (Table 7).
Similarly, it seems clear that treatment with LPS, and
LPS plus quercetin, dexamethasone or δ-tocotrienol, or
inhibitors alone also affects the canonical pathways as
well. The individual genes that were either up-regulated
or down-regulated by the various treatments are
described in Tables 8, 9, and 10.
Out of several genes up-regulated or down-regulated
with quercetin, 22 were associated with inflammation,
and ageing process, which include gene expression of
T R A F 1 ,C C L 8 ,V C A M 1 ,R A S G R P 1 ,T N F - a,I L - 1 a,
ABCC, and LRRN6A etc, which function in signaling,
transcription, NF-B, chemokine, protein synthesis, and
only 10 genes down-regulated were associated with age-
ing process, such as ABCT, RASGRP3, PHKA, UBE2D
and RIKEN cDNA were modulated by quercetin signifi-
cantly (Table 8). The complete description and function
of above mentioned genes is reported in Table 8.
Similarly, there were only 21 similar genes as reported
for quercetin that were up-regulated and 10 genes
down-regulated associated directly or indirectly with
inflammation, and ageing process by δ-tocotrienol
(Table 9). The genes whose expression was up-regulated
by quercetin or δ-tocotrienol included Tgtp (T cell spe-
cific GTPase), TRAF1 (TNF receptor associated factor
1), VCAM1 (vascular cell adhesion molecule 1), ABCC
(ATP-binding cassette, subfamily C), IL-1a (interleukin-
1a), and gene expression down-regulated by quercetin
and δ-tocotrienol included RASGRP3 (RAS guanyl
releasing protein 3), IFBGR1 (interferon gamma receptor
1), PHKA2 (phosphorylase kinase-a2), UBE2D (ubiqui-
tin conjugating enzyme E2D2) and RIKEN cDNA (Table
9).
T h ee x p r e s s i o no f2 5g e n e sw e r eu p - r e g u l a t e da n d1 2
genes down-regulated responsible for the modulation of
inflammation, and ageing process, which were impacted
by dexamethasone treatment (Table 10). The important
genes up-regulated with dexamethasone were CD40
(CD40 antigen belongs to TNF receptor superfamily),
USP9 (ubiquitin specific protease 9), IL-1RA (interleukin
1 receptor antagonist), VCAM1 (vascular cell adhesion
molecule), CCL8 (chemokine [C-C motif] ligand 8), NF-
Table 7 Effects of LPS, or LPS + with and without quercetin (Quer), δ-tocotrienol (δ-Trie) or dexamethasone (Dexa) on
canonicallpathways in liver samples of C57BL/6 male mice.
# Functions LPS LPS + Quer Quer LPS + δ-Trie δ-Trie འ LPS + Dexa Dexa
1 C21-Steroid Hormone Metabolism 11 9 8
2 Notch Signaling 25 19 23 20 22
3 Serotonin Receptor Signaling 14 13 13 10 11 11
4 Tyrosine Metabolism 21 20 23 16
5 Taurine and Hypotaurine Metabolism 7 6 6 7 6 6
6 Retinol Metabolism 5 5 5 4
7 Toll-like Receptor Signaling 31 24 31 30
8 Bile Acid Synthesis 20
9 Histidine Metabolism 16
10 Nitric Oxide Signaling in Cardiovascular 27
11 FGF Signaling 32
12 GABA Receptor Signaling 24 21 22
13 Dopamine Receptor Signaling 20 19
14 Sulfur Metabolism 5 4 5 4
15 Valine, Leucine, Isoleucine Degradation 17 6
16 Alanine and Aspartate Metabolism 16
17 Tryptophan Metabolism 35 11 43 39
18 Phenylalanine, Tyrosine Biosynthesis 15
19 Cysteine Metabolism 7 7 7
20 Pantothenate & CoA Biosynthesis 34 30
21 Nicotinate & Nicotinamide Metabolism 16
22 Prostaglandin & Leukotriene Metabolism 30 26
23 Fatty Acid Biosynthesis 5 4 4
1The data in this Table represents the expression of a number of genes modulated by various treatments. Macrophages were treated with LPS (10 ng/well),
quercetin (40 μM), δ-tocotrienol (20 μM), or dexamethasone (10 μM) with and without LPS (10 ng/well) as described in the experimental section. Total RNA was
extracted from the various treated cells and their gene expression profiles compared with the control (LPS), and untreated cells. The values here haveb e e n
corrected for differences in the arrays. The gene expression values are reported as average normalization log ratios. A data set containing gene identifiers and
their corresponding expression values were uploaded as an Excel spreadsheet using the template provided in the Ingenuity Pathway Analysis programm Various
functions, their location, and gene expression values in this table represent for inhibitors only. The details of comparison for specific gene expression for each
inhibitor were reported in Tables 8,9,10.
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Page 17 of 22B1 (nuclear factor of kappa B light polypeptide gene),
PKI (protein kinase inhibitor), and RIKEN cDNA
(9230106B05 gene) as shown in Table 10. The most
important genes that were down-regulated due to dexa-
methasone treatment were ABCD (ATP-binding pro-
tein), RASGRP3 (ras guanyl releasing protein 3), PHKA2
(phosphorylase kinase, alpha2) and LRRN1 (leucine rich
repeat neuronal 1), as shown in Table 10.
All the genes that were either up-regulated or down-
regulated by quercetin, δ-tocotrienol, or dexamethasone
described above were associated with transcription regu-
lators, transcription receptors, cytokines, and kinases
( T a b l e s8 ,9 ,a n d1 0 ) .T h em a x i m u mn u m b e ro fg e n e
expression modulated by above mentioned inhibitors
also influenced lipid metabolism, immune responses,
sterol and bile acid biosynthesis, catalytic activity, blood
coagulation, oxidoreductase activities, phosphotransfer-
ase activities, antigen processing, metal ion binding,
RNA binding, and nucleic acid binding proteins (Tables
8, 9, and 10). In summary, the present preliminary
results from the DNA-array followed by pathway ana-
lyses have shown that quercetin, δ-tocotrienol or dexa-
methasone inhibit LPS-stimulated gene expression at
numerous points of the signaling pathways. The up-reg-
ulation and down-regulation of different genes in the
pathway with each treatment is presented in Tables 8, 9,
Table 8 Microarray analyses of RNA after treatment with LPS, LPS + quercetin or quercetin of macrophages from
C57BL/6 male mice.
Ageing: Genes Up-regulated by LPS
# Genes LPS LPS + Quercetin Quercetin Description Function
1 IL-6 (IFNb2) 341.52 124.92 -1.03 Interleukin 6 (interferon b2) NF-B & IL-6 Signaling
2 CD40 258.44 28.36 1.40 CD40 antigen (TNF receptor superfamily mem-5) Signaling
3 IL-1b 249.03 38.18 1.02 Interleukin 1b NF-B & IL-6 Signaling
4 IFIPT 186.05 136.24 -4.67 Interferon induced protein with tetratrocopeptide Protein
5 TRAF1 150.74 23.09 -1.97 TNF receptor associated factor 1 Signaling
6 IL1RA 125.10 113.37 34.71 Interleukin 1 receptor antagonist Signaling
7 CD69 105.21 13.35 -3.79 CD69 antigen (P60, early T-cell activation antigen) Antigen
8 CCND2 101.08 28.46 -4.39 Cyclin D2 Cell cycle
9 VCAM1 95.41 25.70 2.42 Vascular cell adhesion molecule Inflammation-linked
10 RASGRP1 90.88 13.71 -9.18 Ras guanyl releasing protein 1 Protein
11 CCL8 87.72 10.33 1.19 Chemokine (C-C motif) ligand 8 Chemokine
12 IL-12b 70.51 5.47 -4.63 Interleukin 12b NF-B & IL-6 Signaling
13 SOCS3 62.94 24.87 -5.22 Suppressor of cytokine signling 3 Anti-inflammation
14 TNF 54.11 47.44 -1.21 Tumor necrosis factor NF-B & IL-6 Signaling
15 SERPIN 46.27 10.85 -1.64 Serine or cysteine proteinase inhibitor Inhibitor
16 ABCC 42.89 -2.02 33.56 ATP-binding cassette, subfamily C Protein
17 ICAM1 41.21 8.51 -3.56 Intercellular adhesion molecule 1 Inflammation-linked
18 IL-1a 39.92 13.49 -1.08 Interleukin 1a NF-kB & IL-6 Signaling
19 UBE2A 10.41 18.06 13.26 Ubiquitin conjugating enzyme E2A Enzyme
20 CNTNA1 5.41 6.35 12.69 Contactin associated proten1 Plasma membrane
21 ATF7 5.05 7.14 13.68 Activating transcription factor 7 Transcriptor
22 LRRN6A 3.42 7.98 4.36 Leucine rich repeat neuronal 6A Enzyme
Ageing Genes Down-regulated by LPS
# Genes LPS LPS + Quercetin Quercetin Description Function
1 ABCD2 -43.36 -48.92 -24.78 ATP-binding cassette, subfamily D member 2 Protein
2 RASGRP3 -36.19 -4.43 -2.46 RAS guanyl releasing protein 3 (GRP3) Protein
3 PTBP2 -32.63 -9.00 -15.35 Polypyrimidine tract binding protein 2 Protein
4 IFNGR1 -28.05 -1.65 -9.69 Interferon gamma receptor 1 Signaling
5 TNP1 -24.67 -3.56 -3.70 Transition protein 1 Protein
6 PHKA2 -22.65 -3.14 4.06 Phosphorylase kinase, alpha 2 (liver) Enzyme
7 UBE2D2 -22.60 1.95 -22.60 Ubiquitin conjugating enzyme E2D2 Enzyme
8 HCAP-G -22.08 -17.67 2.86 Chromosome condensation protein G Protein
9 4930503816 -22.71 -6.24 -6.36 RIKEN cDNA Enzyme
10 NFATC -5.60 -3.01 -41.42 Nuclear factor of activated T cells cytoplasmic Transcriptor
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Page 18 of 22and 10. These results show that LPS up-regulates
expression of several important genes associated with
ageing and pro-inflammation (CCL8, NF-B1, VCAM1,
PK1, RIKEN cDNA, PHKA, IFBGR, LRRN, IL-1b, IL-1a,
IL-6, TNF-a,I L - 1 2 ,i N O S ,V C A M 1 ,I C A M 1 ,C O X 2 ,
IL1RA, TRAF1, CD40) and whose expression was inhib-
ited by quercetin and δ-tocotrienol. The present results
also suggest that approximately 90% of LPS-inducible
macrophage genes are inhibited by quercetin, δ-tocotrie-
nol and dexamethasone.
Discussion
The key finding of the present study was that diet sup-
plementation with quercetin or δ-tocotrienol for 4
weeks resulted in decreased expression levels of mRNA
for TNF-a and iNOS genes and decreased secretion of
TNF-a protein and production of NO by LPS-stimu-
lated macrophages from both senescent and young
mice. Stimulation of macrophages with either IFN-b or
IFN-g in addition to LPS significantly and markedly
enhanced NO production compared to stimulation with
LPS alone. Again, however, diet supplementation with
quercetin or δ-tocotrienol for 4 weeks suppressed NO
production by macrophages from both senescent and
young mice when stimulated with LPS and either IFN-b
or IFN-g.W ea l s od e m o n s t r a t e dt h a tN Ol e v e l sa n d
iNOS mRNA expression levels were significantly higher
in LPS-stimulated macrophages from senescent,
Table 9 Microarray analyses of RNA after treatment with LPS, LPS + δ-tocotrienol, or δ-tocotrienol of macrophages
from C57BL/6 male mice.
Genes Up-regulated by LPS
# Genes LPS LPS + δ-Tocotrienol δ-Tocotrienol Description Function
1 IL-6 (IFNb2) 341.52 184.38 8.74 Interleukin 6 (interferon b2) NF-B & IL-6 Signaling
2 CD40 258.44 104.31 3.75 CD40 antigen (TNF receptor superfamily mem-5) Signaling
3 IL-1b 249.03 126.71 1.07 Interleukin 1b NF-B & IL-6 Signaling
4 IFPIT 186.05 143.32 -3.77 Interferon induced protein with tetratrocopeptide Protein
5 Tgtp 78.14 40.54 1.29 T cell specific GTPase Enzume
6 TRAF1 150.74 89.04 4.06 TNF receptor associated factor 1 Signaling
7 IL-1RA 125.74 175.73 57.18 Interleukin-1 receptor antagonist Signaling
8 CD69 105.21 41.59 1.10 CD69 antigen (P60, early T-cell activation antigen) Antigen
9 CCND2 101.81 43.91 5.33 Cyclin D2 Cell cycle
10 VCAM1 95.41 63.90 -4.94 Vascular cell adhesion molecule Inflammation-linked
11 RASGRP1 90.88 47.77 3.81 Ras guanyl releasing protein 1 Protein
12 CCL8 87.72 11.31 -1.05 Chemokine (C-C motif) ligand 8 Chemokine
13 IL-12b 70.51 34.17 -1.68 Interleukin12b NF-B & IL-6 Signaling
14 SOCS3 62.94 39.81 -2.92 Suppressor of cytokine signalling 3 Anti-inflammation
15 TNF 54.11 53.41 -1.98 Tumor Necrosis factor NF-B & IL-6 Signaling
16 SERPIN 46.27 44.43 1.05 Serine or cysteine proteinase inhibitor Inhibitor
17 ABCC 42.89 -5.22 5.00 ATP-binding cassette, subfamily C Protein
18 ICAM1 41.21 29.89 -1.11 Intercellular adhesion molecule 1 Inflammation-linked
19 IL-1a 39.92 32.79 1.58 Interleukin 1a NF-B & IL-6 Signaling
20 ATP2A2 24.00 48.36 57.91 AtPase, Ca++ transporting cardiac muscle twitch Enzyme
21 ACTL6B 22.49 23.29 14.23 Actin-like 6B Protein
Genes Down-regulated by LPS
# Genes LPS LPS + δ-Tocotrienol δ-Tocotrienol Description Function
1 ABCD2 -43.36 -39.75 -5.51 ATP-binding cassette, subfamily D member 2 Protein
2 RASGRP3 -36.19 -19.54 -1.07 RAS guanyl releasing protein 3 (GRP3) Protein
3 PTBP2 -32.63 -2.64 2.20 Polypyrimidine tract binding protein 2 Protein
4 IFNGR1 -28.05 -4.72 -3.75 Interferon gamma receptor 1 Signaling
5 TNP1 -24.67 -13.88 -2.87 Transition protein 1 Protein
6 PHKA2 -22.65 -6.95 2.71 Phosphorylase kinase, alpha 2 (liver) Enzyme
7 UBE2D2 -22.60 -17.39 -7.53 Ubiquitin conjugating enzyme E2D2 Enzyme
8 4930503B16 -22.71 -1.18 -2.11 RIKEN cDNA gene Enzyme
9 PSMB2 -1.44 -1.91 -25.58 Proteasome (prosome macropain) subunit, b-type 2 Peotidase
10 GIMAP1 -1.205 -3.16 -20.29 GTPase, IMP family member 1 Ion Exchange
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Page 19 of 22Table 10 Microarray analyses of RNA after treatment with LPS, LPS + dexamethasone (Dexa), or dexamethasone
(Dexa) of macrophages from 8-week-old C57BL/6 male mice.
Ageing Genes Up-regulated by LPS
# Genes LPS LPS +
Dexa
Dexa Description function
1 IL-6 (IFNb2) 341.52 100.53 1.21 Interleukin 6 (interferon b2) NF-B & IL-6
Signaling
2 CD40 258.44 100.54 6.03 CD40 antigen (TNF receptor superfamily) Signaling
3 IL-1b 249.03 46.52 2.09 Interleukin-1b NF-B & IL-6
Signaling
4 IFIPT 186.05 90.83 -6.37 Interferon Induced protein with
tetrarocopeptide
Protein
5 HD 152.95 8.62 3.78 Histidine decarboxylase Enzyme
6 TRAF1 150.74 73.45 -1.74 TNF receptor-associated factor 1 Signaling
7 USP9 134.50 105.70 76.70 Ubiquitin specific protease 9 Peptidase
8 IL1RA 125.10 74.86 40.46 Interleukin 1 receptor antagonist Signaling
9 CD69 105.21 37.08 -1.79 CD69 Antigen (p60, early T-cell activation) Antigen
10 VCAM1 95.405 31.684 -3.435 Vascular cell adhesion molecule Cell cycle
11 RASGRP1 90.88 13.61 1.89 RAS guanyl releasing protein 1 Inflammation-linked
12 CCL8 87.72 5.59 1.46 Chemokine (C-C motif) ligand 8 Chemokine
13 SERPIN 46.27 3.35 -2.34 Serine or cysteine proteinase inhibitor Inhibitor
14 ABCC 42.89 -3.86 9.67 ATP-binding cassette, subfamily C Protein
15 ICAM1 41.21 30.85 -2.12 Intercellular adhesion molecule 1 Inflammation-linked
16 IL1a 39.92 12.01 -1.90 Interleukin 1a NF-B & IL-6
Signaling
17 LRRC17 31.20 24.00 9.72 Leucine rich repeat containing 17 Inhibitor
18 IL-12a 29.59 6.65 2.16 Interleukine-Natural killer cell stimulatory
factor 1
NF-B & IL-6
Signaling
19 TNFAIP 25.39 26.59 5.04 Tumor necrosis factor, ?-induced protein 3 Anti-inflammation
20 NFKBI 25.15 24.08 1.94 Nuclear factor of kappa light polypeptide
gene
Transcription
regulator
21 ATP2A2 24.00 30.09 53.82 ATPase, Ca++ transporting, cardiac muscle Enzyme
22 9230106B05 13.48 27.43 119.10 RIKEN cDNA 9230106Bo5 gene Enzyme
23 UBE2 10.41 4.56 32.53 Ubiquitin conjugating enzyme E 2A Enzyme
24 ABCC 10.11 3.67 27.22 ATP-binding cassette, subfamily C Protein
25 PKI 3.87 5.93 29.40 Protein Kinase (cAMP-dependent catalytic
inhibi)
Enzyme
Ageing Genes Down-regulated by
LPS
# Genes LPS LPS +
Dexa
Dexamethasone Description function
1 ABCD2 -43.36 -2.06 4.69 ATP-binding cassette, subfamily D member
2
Protein
2 RASGRP3 -36.19 -46.69 -1.39 RAS guanyl releasing protein 3 (GRP3) Protein
3 PTBP2 -32.63 -11.47 -6.69 Polypyrimidine tract binding protein 2 Protein
4 IFNGR1 -28.05 -16.15 -2.4 Interferon gamma receptor 1 Signaling
5 TNP1 -24.67 -13.06 -2.92 Transition protein 1 Protein
6 4930503B16 -22.71 -6.49 -2.08 RIKEN cDNA gene Enzyme
7 PHKA2 -22.65 -7.54 3.32 Phosphorylase kinase, alpha 2 (liver) Enzyme
8 UBE2D2 -22.6 -10.76 -18.83 Ubiquitin conjugating enzyme E2D2 Enzyme
9 HCAP-G -22.08 -3.55 -4.89 Chromosome condensation protein G Protein
10 ATP6V1H -1.52 -1.36 -18.75 ATPase, H+ trrransporting lysosomal V1 Transport
11 LRRN1 -1.51 -500 -12.78 Leucine rich repeat neuronal 1 Enzyme
12 PRKGII -1.39 -5.34 -17.23 Protein kinase, cGMP-dependent type II Kinase
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Page 20 of 22compared to young mice. In contrast, age did not
appear to impact levels of TNF-a protein or mRNA
expression levels in LPS-stimulated macrophages (Table
3).
Results of the current study of diet supplementation
with quercetin and δ-tocotrienol confirm and extend
our earlier findings that these same compounds inhib-
ited NO production and TNF-a secretion by LPS-stimu-
lated murine macrophages in vitro,a n dt h a ts e r u mN O
and TNF-a levels were reduced in chickens fed diets
supplemented with quercetin or δ-tocotrienol [3,5]. In
view of evidence linking dysregulated inflammatory
responses to a variety of age-associated diseases (e.g.
cancer, cardiovascular disease, dementia), our collective
findings that diet supplementation with two widely
available, inexpensive, non-t o x i cp r o t e a s o m ei n h i b i t o r s
suppress inflammatory responses in mice and chickens,
particularly in senescence, raises the prospect that diet
supplementation with these agents could have beneficial
health effects in ageing humans.
Quercetin and δ-tocotrienol are common, naturally
occurring compounds as reported in detail in our recent
publication [5], are commercially available as dietary
supplements, and possess antioxidant, antithrombotic,
anticarcinogenic and anti-inflammatory properties
[8,16,17]. Quercetin and δ-tocotrienol have been shown
to inhibit macrophage proliferation and activation in
vitro by blocking the activation of LPS-stimulated NF-
B signaling [18-22]. Their inhibitory effect on the pro-
duction of nitric oxide (NO) has been attributed to their
antioxidant and free-radical scavenging properties
[23,24]. Recently, we have described the detailed
mechanism by which these compounds regulate the pro-
duction of NO and pro-inflammatory cytokines [3]. We
reported that proteasome inhibition by quercetin and δ-
tocotrienol results in decreased proteolytic degradation
of P-IB which, in turn, decreases translocation of acti-
vated NFB to the nucleus, and depresses transcription
of TNF-a and iNOS genes [3]. These compounds
appear to be relatively potent inhibitors of multiple pro-
teasome subunits that are critically engaged in regulat-
ing inflammatory mediator/s in ageing processes [3].
The microarray data of quercetin and δ-tocotrienol
support the involvement NF-B and TLRs pathways for
the regulation of production of nitric oxide as reported
in Tables 4 - 10. The results from the DNA-array fol-
lowed by pathway analyses have shown that quercetin,
δ-tocotrienol, inhibits LPS-stimulated gene expression at
numerous points. The up-regulation and down-regula-
tion of different genes in the pathway from each treat-
ment are presented in Tables 8 - 10. These results
showed LPS-induced up-regulation or down-regulation
of expression of several important genes associated with
ageing and pro-inflammatory (NF-B1, VCAM1, PKI,
RIKEN cDNA, PHKA, LRRN, IL-1b,I L - 1 a,I L - 6 ,T N F -
a, IL-12, iNOS, ICAM1, IL1RA, TRAF1 and CD40)
were inhibited by quercetin, δ-tocotrienol and dexa-
methasone. The present results also suggest that
approximately 70% - 90% of LPS-stimulated macrophage
genes were inhibited by quercetin and δ-tocotrienol.
Therefore, effect of these compounds on many of the
pathways identified by such studies combined use of the
gene-chip array, coupled with the Ingenuity Pathway
Analysis may provide definite information for identifying
additional novel signaling pathways that are affected
positively or negatively by these compounds (Tables 4 -
10).
Conclusions
Recently, a great number of plant-derived substances
have been evaluated as possible inhibitors of the NF-B
pathway. NF-B is activated by pro-inflammatory sti-
muli such as TNF-a,L P S ,a n dc o n t r o l st h ee x p r e s s i o n
of genes encoding the pro-inflammatory cytokine (TNF-
a), as well as production of NO and iNOS enzyme. The
majority of these compounds are antioxidants and act
by blocking the phosphorylated and ubiquitinated IB
degradation by the proteasome, thereby preventing NF-
B activation. The results from the DNA-array followed
by pathway analyses have shown that quercetin and δ-
tocotrienol inhibit LPS-stimulated gene expression at
numerous points. These results showed LPS-induced
up-regulation or down-regulation of expression of sev-
eral important genes associated with ageing and pro-
inflammatory (NF-B 1 ,V C A M 1 ,P K I ,R I K E Nc D N A ,
PHKA, LRRN, IL-1a,I L - 6 ,T N F - a,I L - 1 2 ,i N O S ,
ICAM1, IL-1RA, and TRAF1) mediators were inhibited
by quercetin and δ-tocotrienol. The present findings of
inhibition of nitric oxide production by quercetin and δ-
tocotrienol may be of clinical significance in host
defense mechanisms against various infections, treating
several inflammatory diseases, including ageing process.
Therefore, the evaluation of the molecular mechanisms
of natural products-induced anti-inflammatory effects
may provide novel means to regulate cellular function
and to control NF-B-dependent gene expression for
therapeutic purposes, and such a new approach towards
the role of nitric oxide in cellular signaling may lead to
improved treatments for major diseases, including cardi-
ovascular disease, diabetes, cancer, ageing and neurode-
generative disorders [25].
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